highperformr logo

CSL Behring's Overview

Total employees32000
HeadquartersKing of Prussia
Founded1916

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. We develop and deliver innovative therapies for people with rare and serious diseases, including those with bleeding disorders, immune deficiencies, and other life-threatening conditions. Our expertise lies in plasma-derived and recombinant therapies. As a member of the CSL Group (ASX:CSL), CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The company is committed to research and development to address unmet medical needs and improve patients' lives worldwide.

Where is CSL Behring's Headquarters?

HQ Function

The King of Prussia headquarters serves as the central hub for CSL Behring's global operations, including executive leadership, strategic planning, research and development oversight, and corporate functions.

Notable Features:

The campus features modern office buildings and advanced laboratory spaces designed to foster collaboration and innovation. It includes facilities for research, product development, and global operational management.

Work Culture:

The work culture at CSL Behring's headquarters is characterized by a strong focus on patient well-being, scientific excellence, integrity, and collaboration. Employees are driven by the company's mission to save and improve lives.

HQ Significance:

This location is significant due to its proximity to other major life science organizations, academic institutions, and a skilled talent pool, facilitating partnerships and innovation in the biopharmaceutical sector.

Values Reflected in HQ: The headquarters reflects CSL Behring's core values of patient focus, innovation, integrity, collaboration, and superior performance through its state-of-the-art research facilities and a collaborative work environment.

Location:

CSL Behring supports a wide range of functions globally, including research and development in multiple specialized centers, state-of-the-art manufacturing facilities across several continents, an extensive plasma collection network (CSL Plasma), and commercial operations in over 100 countries. This ensures the development, production, and delivery of its life-saving therapies to patients worldwide.

Street Address:

1020 First Avenue

City:

King of Prussia

State/Province:

Pennsylvania

Country:

USA

CSL Behring's Global Presence

Marburg, Germany

Address: Emil-von-Behring-Strasse 76, 35041 Marburg, Germany

Serves as a key operational center for Europe, focusing on manufacturing excellence, research, and development for plasma-derived therapies.

Bern, Switzerland

Address: Wankdorfstrasse 10, 3014 Bern, Switzerland

Focuses on innovation in immunology and coagulation, supporting the development and supply of products for the European and global markets.

Broadmeadows, Victoria, Australia

Address: 189-209 Camp Road, Broadmeadows VIC 3047, Australia

Key hub for the Asia-Pacific region, involved in the end-to-end process from research to manufacturing and distribution of biotherapies and vaccines.

Buying Intent Signals for CSL Behring

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of CSL Behring

As of April 2025, CSL Behring' leadership includes:

Dr. Paul McKenzie - Chief Executive Officer and Managing Director, CSL
Joy Linton - Chief Financial Officer, CSL
Dr. Bill Mezzanotte - Executive Vice President, Head of Research & Development and Chief Medical Officer, CSL
Andy Schmeltz - Executive Vice President, Head of CSL Behring Commercial Operations
Greg Boss - Executive Vice President, Chief Technical Operations Officer, CSL

Investors of CSL Behring

CSL Behring has been backed by several prominent investors over the years, including:

CSL Behring is a business of CSL Limited, which is a publicly traded company on the Australian Securities Exchange (ASX:CSL). Therefore, its investors are the shareholders of CSL Limited. Major institutional investors of CSL Limited typically include large asset managers and pension funds globally.

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

CSL Limited, the parent company of CSL Behring, experienced a significant leadership transition with the appointment of a new CEO.

Departures

Paul Perreault, Paul Perreault retired as CEO and Managing Director of CSL.

New Appointments:

Dr. Paul McKenzie, Dr. Paul McKenzie appointed as CEO and Managing Director of CSL.

Technology (Tech Stack) used by CSL Behring

Discover the tools CSL Behring uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

CSL Behring Email Formats and Examples

CSL Behring commonly uses the firstname.lastname@cslbehring.com email format for its employees. Variations may exist for specific departments or regions, but this is the most prevalent structure.

firstname.lastname@cslbehring.com

Format

john.doe@cslbehring.com

Example

90%

Success rate

News and media

CSL NewsMay 7, 2024

CSL Behring news title: FDA Approves Self-Administration of CSL Behring's Hizentra® via Subcutaneous Infusion Pump

CSL Behring announced that the U.S. Food and Drug Administration (FDA) has approved a new dosing option for Hizentra® (Immune Globulin Subcutaneous [Human], 20% Liquid) that allows for self-administration using an infusion pump. This provides greater flexibility for patients with primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP)....more

CSL NewsApril 30, 2024

CSL Behring news title: CSL Reports Positive Topline Results from Phase 3 Trial of Garadacimab (Anti-Factor XIIa Monoclonal Antibody) for Prophylactic Treatment of Hereditary Angioedema (HAE)

CSL announced positive topline results from the VANGUARD Phase 3 clinical trial evaluating the efficacy and safety of garadacimab (CSL312) as a prophylactic treatment for patients with hereditary angioedema (HAE). The study met its primary efficacy endpoint....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including CSL Behring, are just a search away.